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Abstract 
Background: We previously reported up-regulation of tigarb (the zebrafish 
orthologue? of human TIGAR, TP53 ±Induced Glycolysis and Apoptosis Regulator) in 
a zebrafish pink1-/- model of 3DUNLQVRQ¶VGLVHDVHPD). Genetic inactivation of tigarb 
led to the rescue of dopaminergic neurons and mitochondrial function in pink-/- 
zebrafish. The aim of this study was to determine the relevance of TIGAR for human 
PD, investigate its disease specificity and identify relevant upstream and downstream 
mechanisms.  
Materials and Methods: TIGAR Immunohistochemistry using a range of 
antibodies was undertaken for detailed assessment of TIGAR in formalin-fixed, 
paraffin-embedded tissue from post mortem brains of PD patients and other 
neurodegenerative disorders (n=10 controls, 10 PD cases, 10 dementia with Lewy 
bodies, 5 motor neurone disease (MND), 3 multiple system atrophy (MSA) and 
complemented by immunohistochemistry for p53, hexokinase I (HK-I) and hexokinase 
II (HK-II; n=4 control, 4 PD, and 4 dementia with Lewy bodies).  
Results: TIGAR was detected in Lewy bodies and Lewy neurites in the 
substantia nigra of sporadic PD and Dementia with Lewy bodies (DLB) patients. 
Staining of adjacent sections confirmed the presence of TIGAR alongside alpha-
synuclein in these LB and Neurites. In contrast, TIGAR-positive aggregates were not 
seen in cortical Lewy bodies. TIGAR protein was also absent in both TDP-43-positive 
inclusions in MND and glial cytoplasmic inclusions in MSA. Subsequent investigation 
of the TIGAR-upstream regulator p53 and the downstream targets HK-I and HK-II in 
PD brains suggested a possible mild increase in HK-I. 
Conclusions: TIGAR protein, is present in SN Lewy bodies of both sporadic PD  
and DLB. The absence of TIGAR protein in the pathological inclusions of MND or MSA 
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suggests disease specificity and further raises the possibility that TIGAR may be 
involved in PD pathogenesis.  
4 
 
1. Introduction 
3DUNLQVRQ¶V GLVHDVH 3' LV D FRPPRQ SURJUHVVLYH QHXURGHJHQHUDWLYH
disorder.  A key pathological hallmark of the disease is loss of dopaminergic neurons 
in the substantia nigra, resulting in the clinical triad of tremor, akinesia and rigidity. A 
further diagnostic pathological feature of PD is the Lewy body, primarily located in the 
substantia nigra, but also found in other brainstem and forebrain locations.  Classical 
substantia nigra Lewy bodies are usually round with a hyaline, eosinophilic core with 
a paler surrounding halo on haematoxylin and eosin staining.  Lewy bodies in the 
forebrain are paler and lack a halo (Spillantini et al., 1997).  Lewy bodies are composed 
mainly of neurofilaments and ubiquitylated proteins, of which alpha-synuclein has 
been recognised as the main component (Licker et al., 2009; Spillantini et al., 1997). 
Immunohistochemistry for alpha-synuclein also reveals neuritic deposits called Lewy 
neurites (LN). Dementia with Lewy bodies (DLB) has considerable clinical and 
SDWKRORJLFDORYHUODSZLWK3DUNLQVRQ¶VGLVHDVH:  It is characterised by Lewy bodies and 
Lewy neurites both in the midbrain and brainstem as well as the forebrain, with many 
patients having Parkinsonian symptoms in addition to dementia (Irwin et al., 2017).  
Lewy bodies are immunoreactive for alpha-synuclein. However, to date, there 
are approximately 300 further molecules that have been identified in Lewy bodies 
(Wakabayashi et al., 2013).  Many of these are protein products of genes found to 
cause PD when mutated, including DJ-1, LRRK2, Parkin and PINK1. In addition, other 
protein constituents of Lewy bodies are known to have roles in mitochondrial function, 
the ubiquitin-proteasome system, aggresome formation and autophagy, suggesting a 
role of these proteins in PD pathogenesis (Velayati et al., 2010; Wakabayashi et al., 
2013).  
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 TIGAR (TP53-Induced Glycolysis and Apoptosis Regulator; also known as 
C12orf5) was identified by Bensaad, et al. 2006. The initial function attributed to this 
protein is to decrease levels of Fructose-2,6-Biphosphate (Fru-2,P2), the substrate of 
Phosphofructokinase-1 (PFK-1), the key enzyme in the glycolytic pathway. By 
lowering the Fru-2,P2 levels, TIGAR inhibits the glycolytic pathway and promotes the 
Pentose Phosphate Pathway (PPP). This, in turn, reduces reactive oxygen species 
(ROS) by increasing the production of NADPH and reduced glutathione (Bensaad et 
al., 2006).  
TIGAR has also been implicated in apoptosis and autophagy. It has been 
suggested that TIGAR can promote apoptosis by inhibiting the glycolytic pathway 
(Bensaad et al., 2006) as well as reacting to raised reactive oxygen species . TIGAR 
can also modulate reactive oxygen species (Bensaad et al., 2009; Ye et al., 2013):  
Increased levels of ROS induce p53, which in turn activates transcription of TIGAR, 
consequently reducing autophagy within the cytoplasm (Cheung et al., 2012). 
We previously established a pink1 mutant (pink1-/-) zebrafish line with a Stop 
mutation in the Pink1 kinase domain and abolished kinase activity. This pink-/- 
zebrafish line was the first vertebrate model of PINK1 deficiency to resemble key 
features of human PD, namely loss of dopaminergic neurons and marked impairment 
of mitochondrial function and morphology.  Genome-wide, unbiased gene expression 
analysis identified marked upregulation of tigarb (the zebrafish homologue of TIGAR) 
mRNA in pink-/- compared to controls. Of note, TigarB knock down normalised 
mitochondrial function and rescued the dopaminergic neurons (Flinn et al., 2013).  This 
suggested a role for TIGAR in PD pathogenesis.  Therefore, we aimed to determine if 
TIGAR is present in the human substantia nigra, and specific for in PD and DLB-
associated pathology.  
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We also sought to determine whether TIGAR upregulation in human 
neurodegenerative disorders is due to upregulation of p53 (see above) and whether it 
may exert its effect in PD via Hexokinase up regulation. (Lee et al., 2015). The 
Hexokinase family are enzymes that are responsible for the conversion of glucose to 
glucose-6-phosphate (G-6P). This is a crucial step in the glycolytic pathway and the 
pentose phosphate pathway. HK-II (hexokinase II) is prevalent in tissues with high 
energy demand, such as skeletal muscle, heart and adipocytes (John et al., 2011). It 
also has an important role in regulating cellular survival and autophagy under glucose 
deprivation conditions or type of cellular damage (Tan and Miyamoto, 2015). 
Overexpression of mitochondrial HK-II may confer neuronal protection and survival in 
animal and cellular models of PD and neurodegeneration (Corona et al., 2010; 
Gimenez-Cassina et al., 2009). Under hypoxic conditions, mitochondrial HK-II is 
important for TIGAR mitochondrial translocation, where both proteins form a complex. 
This results in HK-II stabilization and enhanced activity and interaction with TIGAR 
upon presence of glucose and active HIF-Į+.-I is present in all cellular types, but 
especially in the cerebral tissue and blood cells. It has been suggested that HK-I 
specifically shunts the glycolytic pathway (John et al., 2011; Magrì et al., 2016). 
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2. Results 
2.1 TIGAR in the substantia nigra 
Immunohistochemistry for TIGAR was performed in the substantia nigra using 
antibodies that recognised either the central region (ab62533 and ab10545) or the C- 
terminal (ab129333, LS-C286858 and PA5-29152) of the protein.  
Antibodies that recognise the C-terminus of TIGAR showed neuronal labelling 
in the cell body and nucleus. Neurons from both controls and 3DUNLQVRQ¶VGLVHDVH
patients showed a variable degree of cytoplasmic labelling ranging from low to high 
levels of expression.  This variability was seen both within cases and between cases.  
TIGAR-positive neurites were also seen in the controls as well as PD and DLB cases. 
Notably, Lewy bodies were positive for TIGAR using all three antisera directed against 
the C terminus (figure 1 and supplementary figure 1).  The presence of TIGAR in Lewy 
bodies was initially observed in all PD and DLB brains from the Sheffield Brain Tissue 
Bank (SBTB), and subsequently confirmed in PD and DLB brains from the Queen 
Square Brain Bank (QSBB). These anti C-terminus antibodies seemed to label a 
UHJLRQRIWKH/HZ\ERG\WKDWLVGHHSWRWKHµKDOR¶EXWGRHVQRW incorporate the most 
central region of the structure. The C-terminus antibodies had largely similar staining 
patterns.   
In the substantia nigra, data for the SBTB cohort suggested that there may be 
a greater proportion of TIGAR-positive neurones in the PD cases compared to controls 
and more TIGAR-positive neurites in the PD (mean=17.5%, standard deviation=5.8, 
n=4) and DLB (mean=15.9%, standard deviation=15.1, n=4) cases compared to 
controls (mean=5.2%, standard deviation=3.06, n=4; Pİ 0.01). However, these 
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findings were not replicated in analysis of a larger cohort of cases (controls, PD and 
DLB n=6 each) from QSBB cases for either the proportion of TIGAR-positive neurones 
or the number of TIGAR-positive neurites (P. The initial finding for the SBTB 
cases thus most probably represents a spurious result and highlights the need to 
analyse case series of sufficient size prior to drawing strong conclusions.  
Antibodies that only label the central region of TIGAR showed some diffuse and 
non-specific cytoplasmic neuronal labelling, as well as some cross-reactivity to 
neuromelanin (supplementary figure 1). There was no difference in the staining pattern 
between PD cases and controls with no labelling of Lewy bodies.  These antibodies 
showed fairly diffuse, non-specific staining of neurones, neuropil with a strong cross 
reaction to neuromelanin.  There was slightly less background staining for the Abcam 
antibody, otherwise the two antibodies gave similar staining patterns.   
2.2 TIGAR Colocalises with alpha-synuclein 
Double-labelling immunohistochemistry for both TIGAR and alpha-synuclein 
was performed with a combination of TIGAR (visualised by fluorescence or DAB) and 
alpha-synuclein (visualised in fluorescence) proved to be rather unreliable such that 
good, interpretable images could only be obtained for 1PD patient for 
DAB/fluorescence and one PD and one DLB patient with double fluorescence.  In 
these cases, colocalisation of TIGAR and alpha-synuclein was demonstrated 
(supplementary figure 2).   
Therefore, to provide further confirmation that the anti TIGAR C-terminus 
antibodies were truly labelling Lewy Bodies, adjacent sections of the substantia nigra 
of four cases of PD were stained for alpha-synuclein and TIGAR.  These slides were 
digitised using a Hamamatsu XR scanner, such that adjacent structures could be 
manually aligned and the same cells and Lewy bodies could be viewed following both 
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alpha-synuclein and TIGAR immunohistochemistry. This confirmed that alpha-
synuclein positive Lewy bodies were also positive for TIGAR (figure 2).   
 
2.3 p53, HK-I and HK-II in SN 
To identify TIGAR-related upstream and downstream mechanisms, we 
undertook immunohistochemistry for p53 (the most crucial upstream regulator of 
TIGAR), as well as for Hexokinase I (HK-I) and II (HK-II), both plausible downstream 
targets of TIGAR.  However, there was no detectable p53 expression in PD, DLB or 
control brains, suggesting that TIGAR activation/aggregation may be triggered by 
other mechanisms.  
Specific immunoreactivity was detected for HK-I, which is well known to be 
abundant in the brain (Aleshin et al., 1998). HK-I was analysed in the SN of four 
controls and four PD brains using ImageJ. The immunoreactivity of each image 
positive for HK-I was somewhat higher for PD cases (mean=67.85%, SD=1.03) than 
controls and reached marginal significance (mean=61.99%, SD=1.73; P=0.0259, 
t=2.942, df=6). Only non-specific immunolabelling with HK-II was observed.  No 
intergroup differences or Lewy body labelling was evident (Supplementary figure 3). 
 
2.4 TIGAR-positive Lewy bodies are not detected in the forebrain  
TIGAR-positive Lewy bodies were not observed in the hippocampus and mesial 
temporal lobe, although Lewy pathology had been confirmed in this locus by alpha-
synuclein immunohistochemistry.  We conclude that hippocampal and cortical Lewy 
bodies do not contain TIGAR protein.   
TIGAR protein again had variable neuronal labelling intensity in the 
hippocampus in the controls and disease cases with some neurones having strong 
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immunoreactivity, while others had much lower levels of immunoreactivity.  TIGAR-
positive neurites were also evident in all groups (figure 3).   
2.5 TIGAR expression does not associate with other pathological cellular 
inclusions 
Immunohistochemistry for the C-terminus of TIGAR was negative in the glial 
cytoplasmic inclusion bodies in the substantia nigra of three cases of multiple system 
atrophy and in the neuronal cytoplasmic TDP-43-positive inclusions in the ventral 
horns of 5 cases of amyotrophic lateral sclerosis/MND.  We therefore conclude that 
the incorporation of TIGAR into pathological inclusions is specific for brain stem Lewy 
bodies in PD and LBD and not a generic feature of all neuropathological proteinaceous 
inclusions.  
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3. Discussion  
This study assessed TIGAR expression in the post mortem human brain of 
patients with 3DUNLQVRQ¶VGLVHDVH3'SDWLHQWVZLWKGHPHQWLDZLWK/HZ\ERGLHV'/%
as well as in multiple system atrophy (MSA) and amyotrophic lateral sclerosis/motor 
neurone disease (MND). TIGAR was present in neuronal cell bodies and some 
neurites in the control and disease cases. Interestingly, three different antibodies 
directed against the C terminus of the protein specifically labelled brainstem Lewy 
bodies only.  These antibodies did not label cortical Lewy bodies, or the alpha-
synuclein-positive glial cytoplasmic inclusions characteristic of MSA.  Lewy body 
labelling was not seen with antibodies against the central portion of TIGAR protein.  
This may be due to TIGAR cleavage prior to incorporation into Lewy bodies or due to 
some other posttranslational modification to the central portion of TIGAR, rendering it 
unavailable for antibody binding. 
The TIGAR labelling of substantia nigra Lewy bodies appeared to be deep to 
WKH µKDOR¶ UHJLRQDURXQGEXWQRW LQ WKHYHU\FRUHRI WKH/HZ\ERG\$VVXPLQJ What 
these structures are probably assembled from inside out, it is likely that TIGAR 
incorporation is a late event in Lewy body formation, as appears to be the case for 
other proteins (Beyer et al., 2009).  
It has been suggested that Lewy body formation could be the result of a cellular 
self-defence mechanism that disposes of and restricts cytotoxic proteins (Fecchio et 
al., 2013).  It is thus possible that the inclusion of TIGAR in Lewy bodies could be the 
result of the same cellular mechanism.  This suggestion is supported by the finding 
that TIGAR knock down rescued dopaminergic cells in our zebrafish model of PD 
(Flinn et al., 2013). However, in other model systems and studies, TIGAR provides 
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antioxidant defence against ROS, cellular stress and hypoxia via its role in the pentose 
phosphate pathway (PPP), as well as providing the nucleotides for DNA synthesis 
(Bensaad et al., 2006) (Bolaños and Heales, 2010).   
Previous studies have assessed TIGAR mRNA (by microarray) and protein 
levels in tissue homogenates of the superior temporal gyrus in post-mortem tissue 
from the brains of Alzheimer patients and controls (Katsel et al., 2013). Microarray 
data and protein levels (assessed by Western blotting) showed reduced levels of 
TIGAR in the AD patient group compared to controls.  This study of tissue 
homogenates is difficult to interpret due to potential intergroup differences in the 
cellular populations present:  It is possible that as the majority of TIGAR protein is 
neuronal, AD-related neuronal loss and reactive gliosis may explain the apparent loss 
of TIGAR.   Alternatively, the neuronal loss may be mild, but there may be loss of 
TIGAR expression within neurones in AD.   
Within individual brains, we found variable expression of TIGAR expression in 
neurones such that some neurones were intensely positive, while others showed only 
background levels of expression. Data from the SBTB cohort of brains suggested a 
greater proportion of strongly TIGAR-positive neurones in both PD and DLB compared 
to the controls. However, this was not replicated in QSBB tissue, highlighting the 
importance of replication studies and larger sample sizes.  More accurate methods 
that would allow TIGAR quantification in specific cell types are required to fully assess 
TIGAR levels and compare them between patients¶ brains and controls.   
The lack of TIGAR staining seen for both the alpha-synuclein-positive glial 
cytoplasmic inclusions typical for MSA and the TDP-43-positive neuronal cytoplasmic 
inclusions observed in MND suggest disease specificity with TIGAR incorporation into 
pathological inclusions being a specific feature of the neuronal alpha-
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synucleinopathies and not pathological proteinaceous inclusions in general.  This is in 
contrast to p62, ubiquitin and many other proteins that are present in the inclusions of 
a wide range of different neurodegenerative disorders. Furthermore, TIGAR 
incorporation into Lewy bodies was only seen in brainstem but not cortical Lewy 
bodies.  This phenomenon has also been seen with respect to isopentenyl 
diphosphate isomerase (Nakamura et al., 2015),. This is unusual, as most Lewy body 
protein components are present in both brainstem and cortical Lewy bodies (e.g, 
alpha-synuclein (Baba et al., 1998; Irizarry et al., 1998; Spillantini et al., 1997) , MAP-
5 (Gai et al., 1996), HDAC6 (Yasuo et al., 2011), Parkin (Schlossmacher et al., 2002), 
cyclin dependent kinase 5 (Takahashi et al., 2000), synphilin-1 (Wakabayashi et al., 
2002). This, together with the morphological differences between brainstem and 
cortical Lewy bodies suggests qualitative differences in molecular composition 
between the two Lewy body types.   
We found a near complete absence of demonstrable p53 expression in the 
midbrain in all groups. This suggests that neither the variable TIGAR expression seen 
in neuronal cells in control or PD/DLB brains nor its presence in brainstem Lewy bodies 
is likely to be due to regulation by p53-dependent pathways.  
Investigation of the TIGAR downstream targets HK-I and HK-II only revealed a 
rather modest increase in HK-I expression in the substantia nigra in PD compared to 
controls that just reached statistical significance (p=0.02) and should be interpreted 
with caution.  
4. Conclusion 
TIGAR is present in Lewy bodies in the substantia nigra of the alpha-
synucleinopathies PD and LBD and co-localises with alpha-synuclein. This suggests 
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a potential role of TIGAR in the formation of Lewy bodies and possibly also in the 
pathogenesis of Lewy body disorders more generally. The TIGAR-positive 
pathological inclusions were only found in the SN in PD and DLB.  TIGAR was absent 
in both TDP-43-positive inclusions in MND, and GCIs in MSA. This suggests TIGAR 
disease-specificity for Lewy body diseases. Further studies are required to elucidate 
the role of TIGAR in the pathogenesis of PD and to investigate if there is any 
relationship to hexokinase expression.   
5. Experimental Procedure 
5.1 Samples 
Post mortem human tissues were obtained from the Sheffield Brain Tissue 
Bank (SBTB) and the Queen Square Brain Bank for Neurological Disorders (QSBB) 
with ethical approval provided by the committees of the two brain banks, as sanctioned 
by the Scotland A Research Ethics Committee (ref 08/MRE00/103; SBTB) and Tissue 
Bank and NeuroResource REC (Ref. 08/H0718/54+5; QSBB). The SBTB provided 
tissue from: the midbrain and hippocampus in four cases of PD, four DLB and four 
matched controls; midbrain from three MSA cases; spinal cord from five 
MND/amyotrophic lateral sclerosis patients and four controls. The QSBB provided 
midbrain sections were from six PD, six DLB and six matched controls (Table 2 and 
3).  PD and DLB were defined on both clinical and pathological criteria. 
 
5.2 Immunohistochemistry  
Immunohistochemistry using a standard avidin-biotin complex (ABC) method 
was performed on 4Pm-thick, formalin-fixed, paraffin-embedded sections. Details of 
the antisera as well as antigen retrieval and immunohistochemistry conditions are 
15 
 
detailed in supplementary table S1.  TIGAR Immunostaining was performed with the 
IntelliPATH FLX Detection Kit and autostainer system (Menarini Diagnostics). For p53, 
slides were stained on the Dako Omnis Automated Slide Stainer using the Dako 
Envision Flex High pH (GV80011) kit. The whole slide images were captured using a 
Hamamatsu NanoZoomer XR slide scanner.  
Double labelling immunohistochemistry was attempted to investigate co 
localisation of TIGAR with alpha-synuclein. Two formats were attempted: 1) anti alpha-
synuclein antibody with Alexa Fluor 488 or 555 and TIGAR labelled with DAB or 2) 
both alpha-synuclein and TIGAR in fluorescence.  Both formats involved incubation 
with Sudan Black to mask auto fluorescent material.   
To further confirm immunostaining of TIGAR in Lewy bodies, adjacent sections 
were immunostained for TIGAR using the PA5-29152 (Thermo Scientific) antibody and 
alpha-synuclein and digitised.  The resultant whole slide images aligned such that the 
same structures could be assessed in the adjacent sections.  
 
5.3 Quantitative histopathology evaluation 
To assess the number of TIGAR-positive and -negative neurones in the 
substantia nigra in PD, DLB and control cases, the digitised whole slide images were 
scrutinised on the Hamamatsu NDP view platform by two experienced 
neuropathologists, one who was blind to diagnosis (JES) and one who was not (JRH). 
The total number of neurones that were positive and negative for TIGAR were counted 
and the percentage of neurones that were positive calculated. There was a 90% inter-
rater agreement between the two observers. The scores for the two raters were 
compared to establish inter-rater reliability.  Only data obtained from the blinded 
pathologist (JS) was used for intergroup comparisons.  To quantify neuritic pathology 
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in the substantia nigra, entorhinal cortex and cortex of the occipitotemporal gyrus, six 
regions of interest per case were randomly captured from the whole slide images at 
20x magnification (405 x 721µm). Intensely-stained neurites in the substantia nigra 
were counted by two blinded researchers (KLRL and LT), and the mean count per 
case calculated. Inter-rater reliability 99.8% showed agreement between the 
observers.  The same group of controls and patients was used to assess the total 
number of TIGAR positive neurites for the controls. 
 
HK-I was quantified using image analysis.  A total of 6 fields per case were 
captured from the SN at 40x objective and were analysed with Image J (Schindelin et 
al., 2012). Each field was divided into 100 equal squares and subjected to colour 
deconvolution. The Shanbhag threshold (Shanbhag, 1994) was applied to the DAB-
only images. Then, the stained area fraction was measured in the fields thresholded. 
The percentage of each image that was positive for DAB staining was assessed. The 
mean of the 100 values across the 6 fields was calculated for each case and used in 
the statistical analysis for each case. 
5.4 Statistical analysis 
Statistical analysis used for TIGAR included t-Test, Kolmogorov-Smirnov test, 
Mann U-:LWKQH\DQG/HYHQH¶VWHVWRQ0LFURVRIW([FHODQG6366,%0 
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Figures 
 
Figure 1:  Immunohistochemical staining of the substantia nigra. 
Immunostaining for TIGAR (DAB ± brown; ThermoScientific PA5-29152 antibody) 
counterstained with haematoxylin (a-c). Representative picture of a control (a), PD (b) 
and DLB (c) cases.  This reveals strong labelling of the neuronal soma in a subset of 
neurones.  Also stained were some neurites and Lewy bodies (red arrows) and 
neurites. Bar=50Pm. 
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Figure 2. Aligned adjacent sections in the substantia nigra. Representative 
images of immunohistochemistry for alpha-synuclein (left panel) and TIGAR (right 
panel; ThermoScientific PA5-29152 antibody) in the SN of a PD case, demonstrating 
the presence of TIGAR in Lewy bodies (red, blue and purple arrows; bar=100µm). 
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Figure 3. TIGAR staining in hippocampus (ThermoScientific PA5-29152 
antibody). Representative image of TIGAR in hippocampal regions CA2 in a control 
(a), PD (b) and DLB (c). TIGAR expression was variable in the pyramidal cells in all 
cases, but no difference was seen between control and disease cases.  Bar=100µm.
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Supplementary figure 1.  Immunohistochemistry for TIGAR using antibodies 
to the central portion and the region of the C terminus of the protein showing labelling 
of Lewy bodies in the C terminus antibodies (arrows). 
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Supplementary figure 2. Double labelling immunohistochemistry for-alpha synuclein.  When 
TIGAR is labelled with DAB (figures a and c; ThermoScientific PA5-29152 antibody), and alpha-
synuclein is labelled in fluorescence (figures b and d) both Lewy bodies (white arrow head) and 
Lewy neurites (blue arrow head) can be seen to co label for both antisera.  When both TIGAR and 
alpha-synuclein  are labelled in fluorescence (figures e-h), there is again, co-localisation  (bar 
=50Pm). 
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Supplementary figure 3.  p53 (a, b, c), HK-I (d, e, f) and HK-II (g, h, i) 
immunohistochemistry in the substantia nigra in control (a, d, g), PD (b, e, h) and DLB 
(c, f, i) cases. Negative Lewy bodies demonstrated by arrow.  HK-I had slightly greater 
immunopositivity than controls on image analysis.  There was no staining for p53 and 
only low-level non specific labelling was seen for HK-II.  Bar=100Pm.  
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ID Sex Diagnosis 
Age at 
death 
(years) 
LP0079/06 M DLB 78 
LP112/06 M DLB 
 
86 
LP003/04 F DLB 66 
LP016/05 M DLB 72 
LP097/09 F sPD 
 
84 
LP052/09 M sPD 76 
LP015/03 F sPD 74 
LP087/03 M sPD 71 
LP073/09 M MSA 69 
LP120/04 F MSA 63 
LP129/01 M MSA 62 
LP014/90 M ALS 
sporadic 51 
LP059/09 F ALS 
sporadic 80 
LP072/05 M ALS 
sporadic 66 
LP094/06 M ALS 
sporadic 71 
LP141/90 M ALS 
sporadic 55 
LP085/07 F Control 59 
LP005/07 M Control 63 
LP098/07 M Control 67 
NA188/96 F Control 82 
LP056/90 M Control 51 
LP309/90 M Control 82 
LP335/90 F Control 29 
 
Supplementary Table S1. Sheffield Brain Bank Tissue used in this study. F, female; 
M, male; sPD, sporadic Parkinson´s Disease; DLB, Dementia of Lewy Bodies; MSA, 
Multiple System Atrophy; ALS Amytrophic lateral sclerosis. 
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ID Sex Diagnosis Age (years) 
P2/10 F sPD 82 
P54/11 M sPD 80 
P89/10 M sPD 77 
P21/12 M sPD 83 
P33/12 M sPD 74 
P22/12 M sPD 85 
P11/11 M DLB 60 
P34/07 M DLB 80 
P28/11 F DLB 86 
P68/10 M DLB 73 
P48/03 F DLB 74 
P80/10 M DLB 67 
P72/07 M Control 85 
P47/11 F Control 79 
P75/10 F Control 83 
P64/11 F Control 80 
P82/10 F Control 87 
P78/06 F Control 68 
Supplementary Table S2. Queen Square Brain Bank Tissue used in this study. F, 
female; M, male; sPD, sporadic Parkinson´s Disease; DLB, Dementia of Lewy 
Bodies
46 
 
 
 
Antibody Region Antigen retrieval Dilution/time 
Anti-TIGAR antibody. Millipore 
(AB10545) 
Polyclonal / rabbit 
KLH-conjugated linear peptide that lies in the central 
region of the protein 
PC, pH9 1:400 / 30 min 
Anti-TIGAR antibody. ABCAM 
(ab62533) 
Polyclonal / rabbit 
Synthetic peptide (Human) of 19 amino acids from a 
region near the centre of TIGAR 
PC, pH9 1:800 / 30 min 
Anti-TIGAR antibody. ABCAM 
(ab129333) 
Polyclonal / rabbit 
 
Synthetic peptide corresponding to a region within C 
terminal amino acids 220-270 of Human TIGAR 
 
PC, pH9 1:750/ 30 min 
*TIGAR Polyclonal antibody 
Thermo Scientific (PA5-29151) 
Polyclonal/rabbit 
PC, pH9 1:400 / 1 hr 
Anti-TIGAR  Antibody LS-C286858 
(LifeSpan Biosciences) 
Polyclonal / rabbit 
PC, pH 1:50 / 1 hr 
Anti alpha-synuclein antibody 
(NCL-L-ASYN) 
Molyclonal / mouse 
Prokaryotic recombinant protein corresponding to the 
majority of the full length alpha-synuclein molecule 
PC, pH9* 1:1000 / 1hr 
Anti-HK-I [4D7]. ABCAM 
(ab105213) 
Molyclonal / mouse 
Recombinant full length protein, corresponding to amino 
acids 1-917. 
PC, pH 1:2000 / 1 hr 
Anti-HK-II. Thermo Fisher (MA5-
14849) 
Molyclonal / rabbit 
Synthetic peptide corresponding to the sequence of 
human HK-II 
PC, pH 1:50 / 1 hr 
Anti-p53 Dako GA616 
Molyclonal / mouse 
Recombinant human wild-type p53 protein. High pH Target 
Retrieval Solution 
NA+ / 20 min 
Supplementary table S3:  Antibodies tested and optimised for immunohistochemistry in Human brain tissue. Hexokinase I (HK-I); Hexokinase II 
(HK-II); Mouse (M), Rabbit (R); Monoclonal (Mono); Polyclonal (Poly); Non applicable (NA) Pressure cooker (PC). * Pre-treatment for 1 hr with 
formic acid followed by antigen retrieval. +Anti-p53 antibody Ready to Use (prediluted). 
